Reducing suboptimal prescribing of glucagon-like peptide mimetics in type 2 diabetes
In 2016, spend on diabetes prescribing — and glucagon-like peptide 1 (GLP-1) mimetics, in particular — at NHS Hastings and Rother Clinical Commissioning Group (CCG) and NHS Eastbourne, Hailsham and Seaford CCG was significantly higher than expected, based on national prescribing pat…